Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Immune Function in Colorectal Cancer Resection
NCT03273231Unknown
- Sponsor
- Yonsei University
- Start
- Sep 2017
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ketamine in colorectal cancer (CRC) (2 arms), sponsored by Yonsei University. Primary endpoint: Natural Killer Cell Cytotoxicity. Status: unknown.
02
Drugs
ketamine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03273231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03273231.